查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1525410

全球数位治疗市场 - 洞察、竞争格局和市场预测（～2030）

Digital Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

由于虚拟医疗服务的普及以及人们对降低医疗保健成本的兴趣的改变，预计在2024年至2030年预测期内，全球数位治疗市场规模将以 27.73%的年复合成长率成长。糖尿病、精神疾病、癌症和心臟衰竭（HF）等慢性疾病的日益流行，以及行动技术、穿戴式装置、人工智慧、机器学习和资料分析等技术的进步，推动了对数位疗法的需求。监理支援、保险覆盖、策略伙伴关係、投资等的推动，这些是推动2024～2030年预测期间整体市场成长的关键因素。

数位疗法的市场动态

根据国际糖尿病联盟（2022年）的资料，2021年全球约有 5.37 亿人患有糖尿病。根据同一资料，预计到2030年，糖尿病患者总数将增加至约6.43亿，到2045年将增加至约7.83亿。

数位治疗应用程式（DTx），例如 Blue Star、Diabeo System、Livongo Diabetes Program 和 Tidepool，使用基于网路的应用程式和云端平台来治疗基于证据的、行为可改变的慢性疾病，包括糖尿病提供实证、个人化和快速的护理点管理。DTx 透过实现患者的积极参与、生活方式的改变、全面的医疗照护和定期监测血糖状态，提高糖尿病管理中的患者依从性、治疗成功率和经济成果。因此，糖尿病盛行率的不断上升增加了对用于糖尿病管理和治疗的数位治疗软体的需求，推动了整个数位治疗市场的发展。

智慧型手机在已开发国家和发展中国家的普及、患者和医疗保健提供者对数位医疗技术的承受能力以及对以患者为中心的护理和综合医疗系统不断成长的需求推动了市场的发展。方式。Kepios表示，2021年4月，全球有42.7亿人使用互联网，占全球人口的60%以上。预计这一数字在未来几年将会增加，大众对智慧健康追踪的意识也预计在未来几年将会提高。

领先公司越来越注重利用医生和患者易于使用的先进技术开发软体，预计将在预测期内推动市场发展。例如，2022年 7月，AmerisourceBergen Corporation 推出了 DTx Connect，这是一个完全整合的订购、配药和履行平台，目的是促进患者获得医生订购的治疗和诊断服务。该平台与电子病历（EMR）集成，使医生可以轻鬆获得处方药和非处方药。

因此，所有上述因素都有助于2024-2030年预测期内数位治疗市场的成长。

然而，网路安全和隐私问题、不稳定的支付模式等可能会限制未来几年数位治疗市场的成长。

北美预计将主导整个数位治疗市场。

预计到2023年，北美将在数位治疗市场中占据所有地区的最高占有率。这一优势是由该地区医生和患者对数位治疗的需求不断成长、慢性病患者数量不断增加、对远距患者监护和远距医疗的需求不断增加以及存在等推动的。

本报告提供了全球数位治疗市场的研究和分析，包括市场规模和预测、驱动因素和挑战、公司和产品概况。

目录

第1章 数位治疗市场报告简介

第2章 数位治疗市场执行摘要

  • 市场概览

第3章 竞争态势

第4章 监理分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第5章 数位治疗市场主要因素分析

  • 数位治疗市场驱动因素
  • 数位治疗市场的限制与挑战
  • 数位治疗市场机会

第6章 波特对数位治疗市场的五力分析

第7章 数位治疗市场评估

  • 依用途
    • 预防
    • 管理
    • 治疗
  • 依适应症
    • 糖尿病
    • 肥胖
    • 心血管疾病
    • 呼吸系统疾病
    • 其他
  • 地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他领域

第8章 数位治疗市场公司与产品简介

  • Limbix Health, Inc
  • GAIA AG
  • BigHealth
  • DarioHealth Corp
  • HYGIEIA
  • Akili, Inc
  • Pear Therapeutics (US), Inc
  • CANARY HEALTH
  • Noom, Inc
  • Omada Health Inc
  • Welldoc, Inc
  • 2Morrow, Inc
  • ResMed
  • Teladoc Health, Inc
  • Fitbit Health Solutions
  • Huma

第9章 KOL观点

第10章 专案方法

第11章 关于 DelveInsight

第12章 免责声明，联络我们

Product Code: DIMDCL0668

Digital Therapeutics Market by Application (Prevention, Management, And Treatment), Indication (Diabetes, Obesity, Cardiovascular Diseases, Respiratory Diseases, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the increasing accessibility of virtual care and shifting focus among the population on lowering healthcare costs

The digital therapeutics market is estimated to grow at a CAGR of 27.73% during the forecast period from 2024 to 2030. The demand for digital therapeutics is being boosted by the increasing prevalence of chronic diseases such as diabetes, mental illness, cancer, and heart failure (HF), advancements in technology such as in mobile technology, wearable devices, artificial intelligence, machine learning, and data analytics, regulatory support, insurance coverage, strategic partnerships and investments, among others are some of the major factors contributing to the overall growth of the digital therapeutics market during the forecast period from 2024 to 2030.

Digital Therapeutics Market Dynamics:

As per the International Diabetes Federation (2022), in 2021, approximately 537 million people were living with diabetes globally. As per the same source, the total number of patients suffering from diabetes is projected to grow to about 643 million patients by the year 2030 and about 783 million people by 2045.

Digital therapeutic applications (DTx) such as Blue Star, Diabeo System, Livongo Diabetes Program, and Tidepool, among others, use web-based applications or cloud platforms to provide an evidence-based, personalized, rapid point-of-care management of chronic, behavior-modifiable conditions, including diabetes mellitus. DTx can improve patient compliance, therapeutic success, and economic outcomes in diabetes management by enabling active patient engagement, lifestyle change, comprehensive medical care, and periodic monitoring of glycemic status. Thus, the rising prevalence of diabetes will increase the demand for digital therapeutic software which are used in the management and treatment of diabetes, thereby propelling the overall market of digital therapeutics.

The market is anticipated to be driven by the rising smartphone adoption in both developed and developing nations, the affordability of digital health technology for patients and providers, and rising demand for patient-centered care and integrated healthcare systems. Kepios stated that 4.27 billion people used the internet worldwide in April 2021, making up more than 60% of the world's population. It is anticipated that this number is expected to increase, so will public awareness of smart health tracking in the upcoming years.

The increasing focus of major key players on developing technologically advanced software with easy access for physicians and patients is expected to propel the market during the forecast period. For instance, in July 2022, AmerisourceBergen Corporation launched DTx Connect, a fully integrated ordering, dispensing, and fulfillment platform that aims to facilitate patient access to physician-ordered therapeutics and diagnostics. The platform integrates with electronic medical records (EMR), giving physicians easy access to prescription and non-prescription therapies.

Therefore, all the above-mentioned factors are contributing to the growth of the digital therapeutics market during the forecast period from 2024 to 2030.

However, cybersecurity and privacy concerns, and unstable payment models, among others may restrict the digital therapeutics market growth in the upcoming years.

Digital Therapeutics Market Segment Analysis:

Digital Therapeutics market by Product (Prevention, Management, and Treatment), Indication (Diabetes, Obesity, Cardiovascular Diseases, Respiratory Diseases, and Others), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World)

In the indication segment of the digital therapeutics market, the obesity category is expected to amass a significant revenue share in the year 2023. This can be attributed to the increasing patient population associated with obesity across the globe.

The World Obesity Atlas 2022, published by the World Obesity Federation, predicted that one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030. Obesity is a major public health challenge that affects almost every country in the world. Globally, obesity rates have been increasing steadily over the last three decades. In almost every region, there are now more people living with obesity than underweight, and if current numbers continue to rise, as many as 1 billion adults, or 12% of the world population, will be living with obesity by 2025. The above-mentioned source also stated that almost 2.3 billion children and adults were living with overweight and obesity, in 2022, globally and if current trends continue, 2.7 billion adults could be living with overweight or obesity by 2025.

The World Health Organization (WHO) European Regional Obesity Report 2022, stated that overweight and obesity affect almost 60% of adults and nearly one in three children (29% of boys and 27% of girls) in the WHO European Region, in 2022.

The use of a digital therapeutics platform in people with obesity and metabolic syndrome can lead to a reduction in both weight and body mass index (BMI), thereby reducing the risk for comorbidities. Digital therapeutic platforms allow clinicians to deliver lifestyle-modification interventions remotely. These interventions have the potential to influence weight loss in people with obesity and metabolic syndrome through the delivery of evidence-based care even in settings that are resource-limited. Thus, the increasing prevalence of obesity and overweight will increase the demand for digital therapeutics for managing and treating obesity and overweight.

Additionally, the WDTx Platform by Wellthy Therapeutics Pvt Ltd. provides a 52-week lifestyle modification program focused on diet, physical activity, weight management, remote patient monitoring, glycemic control, and blood pressure control. The platform provides artificial intelligence-augmented healthcare tracking, evidence-backed content, and personalized health coach support.

Thus, all the above-mentioned factors are likely to propel the demand for obesity-managing digital therapeutics, thereby contributing to the growth of the digital therapeutics market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall digital therapeutics market:

North America is expected to account for the highest proportion of the Digital Therapeutics market in 2023, out of all regions. This domination is due to the increasing demand for digital therapeutics among the physicians and patients in the region, the increasing patient pool suffering from chronic diseases, the rising demand for remote patient monitoring and telemedicine, the presence of key market players, among factors contributing to the growth of the digital therapeutics market in North America.

According to Administration for Community Living, an operating division of the U.S. Department of Health and Human Services (2024) stated that in the year 2022, individuals aged 65 and older comprised 17.3% of the population. This percentage is projected to increase to 22% by the year 2040.

Thus rising burden of the geriatric population in the region will increase the demand for digital therapeutics as elderly patients are more prone to chronic diseases including major depressive disorder (MDD), which can significantly impair their quality of life. Digital therapeutics offer a viable solution by providing accessible, scalable, and cost-effective tools that can be used alongside traditional treatments.

The favorable regulatory approvals by the authorities will propel the overall market for digital therapeutics in the region. For instance, in April 2024, the U.S. Food and Drug Administration (FDA) granted marketing clearance to Otsuka America Pharmaceutical, Inc. for Rejoyn, a prescription digital therapeutic smartphone application. The app is designed for the treatment of Major Depressive Disorder (MDD) as an adjunct to clinician-managed outpatient care for adult patients aged 22 years and older who are currently on antidepressant medication.

Furthermore, the growing healthcare IT expenditure to advance infrastructure, technological literacy, readiness to adopt advanced technological solutions, favorable government initiatives, the emergence of startups, lucrative funding options growing smartphone penetration, and advancements in internet connectivity, will propel the demand for digital therapeutics in North America.

Some of the major players of digital therapeutics in the North America region are Proteus Digital Health, Inc., Omada Health, Inc., WellDoc, Inc., and Livongo Health, Inc., among others.

Thus, due to the interplay of all the above-mentioned factors, it will lead to an increase in North America digital therapeutics market growth during the forecast period from 2024 to 2030.

Digital Therapeutics Market key Players:

Some of the key market players operating in the Digital Therapeutics market include Limbix Health, Inc, GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc, Pear Therapeutics (US), Inc, CANARY HEALTH, Noom, Inc, Omada Health Inc, Welldoc, Inc, 2Morrow, Inc, ResMed, Teladoc Health, Inc, Fitbit Health Solutions, Huma, and others.

Recent Developmental Activities in the Digital Therapeutics Market:

  • In January 2023, Lupin Digital Health, a wholly-owned subsidiary of global pharma major Lupin Limited, launched its digital therapeutics solution, LYFE. LYFE is India's only evidence-based holistic heart care program that significantly reduces the risk of a heart attack and improves vitals and quality of life for cardiac patients
  • In June 2023, Huma, a leading global digital health company announced the U.S. Food and Drug Administration (FDA) Class II clearance for its disease-agnostic Software as a Medical Device (SaMD) platform.
  • In May 2022, International digital therapeutics innovator, Sidekick Health, launched an integrated digital therapeutics solution for improving the outcomes of patients with Atopic Dermatitis (AD) in conjunction with Pfizer Inc.
  • In April 2021, Mahana Therapeutics, Inc. received the US FDA 510(K) marketing clearance for its Mahana Parallel Digital Cognitive Behavioral Therapy (CBT) mobile application, which was substantially equivalent to a marketed predicate device for Irritable Bowel Syndrome (IBS).

Key Takeaways from the Digital Therapeutics Market Report Study

  • Market size analysis for current Digital Therapeutics market size (2023), and market forecast for 6 years (2024 to 2030)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the digital therapeutics market
  • Various opportunities available for the other competitors in the digital therapeutics market space
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current digital therapeutics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for digital therapeutics market growth in the coming future?

Target audience who can be benefited from this Digital Therapeutics Market Report Study

  • Digital therapeutics products providers
  • Research organizations and consulting companies
  • Digital therapeutics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in digital therapeutics
  • Various end-users who want to know more about the digital therapeutics market and the latest technological developments in the digital therapeutics market.

Frequently Asked Questions for the Digital Therapeutics Market:

1. What are digital therapeutics?

Digital Therapeutics (DTx) are evidence-based therapeutic interventions driven by software to prevent, manage, or treat a medical disorder or disease. In other words, DTx is a patient-facing software application that helps patients treat, prevent, or manage the disease and that has proven clinical benefits.

2. What is the market for digital therapeutics?

The digital therapeutics market is estimated to grow at a CAGR of 27.73% during the forecast period from 2024 to 2030.

3. What are the drivers for the digital therapeutics market?

The digital therapeutics market is slated to witness prosperity owing to the growing geriatric population prone to chronic diseases, the rising number of patients pool suffering from chronic diseases, the increasing usage of smartphones for digital therapeutics, the rising use of health monitoring apps, the cost-effectiveness of digital health technology for providers & patients, and increasing demand for integrated healthcare systems & patient-centric care among others, thereby contribute to the overall growth of the digital therapeutics market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the digital therapeutics market?

Some of the key market players operating in Digital Therapeutics include Limbix Health, Inc, GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc, Pear Therapeutics (US), Inc, CANARY HEALTH, Noom, Inc, Omada Health Inc, Welldoc, Inc, 2Morrow, Inc, ResMed, Teladoc Health, Inc, Fitbit Health Solutions, Huma, and others.

5. Which region has the highest share in the digital therapeutics market?

North America is expected to dominate the overall Digital Therapeutics market during the forecast period from 2024 to 2030. This is owing to the growing prevalence of chronic disorders such as diabetes, cardiovascular diseases, and cancers, among others, and the increasing geriatric population prone to chronic diseases will positively impact the North American digital therapeutics market. Furthermore, high disposable income, sophisticated healthcare infrastructure, incremental healthcare expenditure, an increasing number of start-ups, a well-developed healthcare sector, and increasing investments for R&D, among others also helped the market growth in this region.

Table of Contents

1. Digital Therapeutics Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Digital Therapeutics Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Digital Therapeutics Market Key Factors Analysis

  • 5.1. Digital Therapeutics Market Drivers
    • 5.1.1. Growing demand for remote patient monitoring and mobile health applications
    • 5.1.2. Increasing prevalence of chronic diseases
    • 5.1.3. Advancements in digital healthcare, IoT, AI, and others
  • 5.2. Digital Therapeutics Market Restraints and Challenges
    • 5.2.1. Cyber security and privacy concerns
    • 5.2.2. Unstable payment models
  • 5.3. Digital Therapeutics Market Opportunities
    • 5.3.1. Increasing supportive initiatives and strategic alliances among key players

6. Digital Therapeutics Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Digital Therapeutics Market Assessment

  • 7.1. By Application
    • 7.1.1. Prevention
    • 7.1.2. Management
    • 7.1.3. Treatment
  • 7.2. By Indication
    • 7.2.1. Diabetes
    • 7.2.2. Obesity
    • 7.2.3. Cardiovascular Diseases
    • 7.2.4. Respiratory Diseases
    • 7.2.5. Others
  • 7.3. By Geography
    • 7.3.1. North America
      • 7.3.1.1. United States Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.1.2. Canada Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.1.3. Mexico Digital Therapeutics Market Size in USD million (2021-2030)
    • 7.3.2. Europe
      • 7.3.2.1. France Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.2.2. Germany Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.2.3. United Kingdom Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.2.4. Italy Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.2.5. Spain Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.2.6. Rest of Europe Digital Therapeutics Market Size in USD million (2021-2030)
    • 7.3.3. Asia-Pacific
      • 7.3.3.1. China Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.3.2. Japan Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.3.3. India Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.3.4. Australia Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.3.5. South Korea Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.3.6. Rest of Asia-Pacific Digital Therapeutics Market Size in USD million (2021-2030)
    • 7.3.4. Rest of the World (RoW)
      • 7.3.4.1. Middle East Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.4.2. Africa Digital Therapeutics Market Size in USD million (2021-2030)
      • 7.3.4.3. South America Digital Therapeutics Market Size in USD million (2021-2030)

8. Digital Therapeutics Market Company and Product Profiles

  • 8.1. Limbix Health, Inc
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. GAIA AG
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. BigHealth
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. DarioHealth Corp
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. HYGIEIA
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Akili, Inc
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Pear Therapeutics (US), Inc
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. CANARY HEALTH
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Noom, Inc
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Omada Health Inc
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Welldoc, Inc
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. 2Morrow, Inc
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. ResMed
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Teladoc Health, Inc
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Fitbit Health Solutions
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Huma
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Digital Therapeutics Market in Global (2021-2030)
  • Table 3: Digital Therapeutics Market in Global by Application (2021-2030)
  • Table 4: Digital Therapeutics Market in Global by Indication (2021-2030)
  • Table 5: Digital Therapeutics Market in Global by Geography (2021-2030)
  • Table 6: Digital Therapeutics Market in North America (2021-2030)
  • Table 7: Digital Therapeutics Market in the United States (2021-2030)
  • Table 8: Digital Therapeutics Market in Canada (2021-2030)
  • Table 9: Digital Therapeutics Market in Mexico (2021-2030)
  • Table 10: Digital Therapeutics Market in Europe (2021-2030)
  • Table 11: Digital Therapeutics Market in France (2021-2030)
  • Table 12: Digital Therapeutics Market in Germany (2021-2030)
  • Table 13: Digital Therapeutics Market in United Kingdom (2021-2030)
  • Table 14: Digital Therapeutics Market in Italy (2021-2030)
  • Table 15: Digital Therapeutics Market in Spain (2021-2030)
  • Table 16: Digital Therapeutics Market in the Rest of Europe (2021-2030)
  • Table 17: Digital Therapeutics Market in Asia-Pacific (2021-2030)
  • Table 18: Digital Therapeutics Market in China (2021-2030)
  • Table 19: Digital Therapeutics Market in Japan (2021-2030)
  • Table 20: Digital Therapeutics Market in India (2021-2030)
  • Table 21: Digital Therapeutics Market in Australia (2021-2030)
  • Table 22: Digital Therapeutics Market in South Korea (2021-2030)
  • Table 23: Digital Therapeutics Market in Rest of Asia-Pacific (2021-2030)
  • Table 24: Digital Therapeutics Market in the Rest of the World (2021-2030)
  • Table 25: Digital Therapeutics Market in the Middle East (2021-2030)
  • Table 26: Digital Therapeutics Market in Africa (2021-2030)
  • Table 27: Digital Therapeutics Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Digital Therapeutics Market in Global (2021-2030)
  • Figure 3: Digital Therapeutics Market in Global by Application (2021-2030)
  • Figure 4: Digital Therapeutics Market in Global by Indication (2021-2030)
  • Figure 5: Digital Therapeutics Market in Global by Geography (2021-2030)
  • Figure 6: Digital Therapeutics Market in North America (2021-2030)
  • Figure 7: Digital Therapeutics Market in the United States (2021-2030)
  • Figure 8: Digital Therapeutics Market in Canada (2021-2030)
  • Figure 9: Digital Therapeutics Market in Mexico (2021-2030)
  • Figure 10: Digital Therapeutics Market in Europe (2021-2030)
  • Figure 11: Digital Therapeutics Market in France (2021-2030)
  • Figure 12: Digital Therapeutics Market in Germany (2021-2030)
  • Figure 13: Digital Therapeutics Market in United Kingdom (2021-2030)
  • Figure 14: Digital Therapeutics Market in Italy (2021-2030)
  • Figure 15: Digital Therapeutics Market in Spain (2021-2030)
  • Figure 16: Digital Therapeutics Market in the Rest of Europe (2021-2030)
  • Figure 17: Digital Therapeutics Market in Asia-Pacific (2021-2030)
  • Figure 18: Digital Therapeutics Market in China (2021-2030)
  • Figure 19: Digital Therapeutics Market in Japan (2021-2030)
  • Figure 20: Digital Therapeutics Market in India (2021-2030)
  • Figure 21: Digital Therapeutics Market in Australia (2021-2030)
  • Figure 22: Digital Therapeutics Market in South Korea (2021-2030)
  • Figure 23: Digital Therapeutics Market in Rest of Asia-Pacific (2021-2030)
  • Figure 24: Digital Therapeutics Market in the Rest of the World (2021-2030)
  • Figure 25: Digital Therapeutics Market in the Middle East (2021-2030)
  • Figure 26: Digital Therapeutics Market in Africa (2021-2030)
  • Figure 27: Digital Therapeutics Market in South America (2021-2030)
  • Figure 28: Market Drivers
  • Figure 29: Market Barriers
  • Figure 30: Marker Opportunities
  • Figure 31: PORTER'S Five Force Analysis